JP2017502047A5 - - Google Patents

Download PDF

Info

Publication number
JP2017502047A5
JP2017502047A5 JP2016542987A JP2016542987A JP2017502047A5 JP 2017502047 A5 JP2017502047 A5 JP 2017502047A5 JP 2016542987 A JP2016542987 A JP 2016542987A JP 2016542987 A JP2016542987 A JP 2016542987A JP 2017502047 A5 JP2017502047 A5 JP 2017502047A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
group
conjugate according
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016542987A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502047A (ja
JP6560681B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2014/000920 external-priority patent/WO2015095953A1/en
Publication of JP2017502047A publication Critical patent/JP2017502047A/ja
Publication of JP2017502047A5 publication Critical patent/JP2017502047A5/ja
Priority to JP2019132496A priority Critical patent/JP6908656B2/ja
Application granted granted Critical
Publication of JP6560681B2 publication Critical patent/JP6560681B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016542987A 2013-12-27 2014-12-29 薬物結合体のためのスルホンアミド含有連結系 Active JP6560681B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019132496A JP6908656B2 (ja) 2013-12-27 2019-07-18 薬物結合体のためのスルホンアミド含有連結系

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361921242P 2013-12-27 2013-12-27
US61/921,242 2013-12-27
US201462051899P 2014-09-17 2014-09-17
US62/051,899 2014-09-17
PCT/CA2014/000920 WO2015095953A1 (en) 2013-12-27 2014-12-29 Sulfonamide-containing linkage systems for drug conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019132496A Division JP6908656B2 (ja) 2013-12-27 2019-07-18 薬物結合体のためのスルホンアミド含有連結系

Publications (3)

Publication Number Publication Date
JP2017502047A JP2017502047A (ja) 2017-01-19
JP2017502047A5 true JP2017502047A5 (OSRAM) 2018-02-22
JP6560681B2 JP6560681B2 (ja) 2019-08-14

Family

ID=53477242

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016542987A Active JP6560681B2 (ja) 2013-12-27 2014-12-29 薬物結合体のためのスルホンアミド含有連結系
JP2019132496A Active JP6908656B2 (ja) 2013-12-27 2019-07-18 薬物結合体のためのスルホンアミド含有連結系

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019132496A Active JP6908656B2 (ja) 2013-12-27 2019-07-18 薬物結合体のためのスルホンアミド含有連結系

Country Status (14)

Country Link
US (2) US11560422B2 (OSRAM)
EP (1) EP3086815B1 (OSRAM)
JP (2) JP6560681B2 (OSRAM)
KR (1) KR102384740B1 (OSRAM)
CN (1) CN106255513B (OSRAM)
AU (1) AU2014373574B2 (OSRAM)
CA (1) CA2935077C (OSRAM)
DK (1) DK3086815T3 (OSRAM)
ES (1) ES2916722T3 (OSRAM)
IL (1) IL246457B (OSRAM)
MX (1) MX384608B (OSRAM)
PL (1) PL3086815T3 (OSRAM)
RU (1) RU2729194C2 (OSRAM)
WO (1) WO2015095953A1 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY174813A (en) 2013-03-15 2020-05-16 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
AU2014373640B2 (en) 2013-12-27 2018-08-30 Var2 Pharmaceuticals Aps VAR2CSA-drug conjugates
CA2935077C (en) 2013-12-27 2022-03-15 Geoffrey C. Winters Sulfonamide-containing linkage systems for drug conjugates
CA2960899C (en) * 2014-09-17 2021-08-17 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
CN112494657B (zh) 2014-10-03 2025-02-11 西纳福克斯股份有限公司 磺酰胺接头、其缀合物及制备方法
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
CN108367043A (zh) 2015-12-04 2018-08-03 西雅图基因公司 季铵化的微管溶素化合物的缀合物
US11590239B2 (en) 2016-02-08 2023-02-28 Synaffix B.V. Antibody-conjugates with improved therapeutic index for targeting CD30 tumours and method for improving therapeutic index of antibody-conjugates
JP2019507741A (ja) * 2016-02-08 2019-03-22 シンアフィックス ビー．ブイ． 治療において使用するためのスルファミドリンカーを含むバイオコンジュゲート
EP3413922B1 (en) 2016-02-08 2025-12-10 SynAffix B.V. Improved sulfamide linkers for use in bioconjugates
SG11201808220VA (en) 2016-03-22 2018-10-30 Merck Sharp & Dohme Allosteric modulators of nicotinic acetylcholine receptors
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
CA3072500A1 (en) 2017-08-10 2019-02-14 Sumitomo Dainippon Pharma Co., Ltd. Hemiasterlin derivatives and antibody-drug conjugates including same
US11795195B2 (en) 2017-08-10 2023-10-24 Sumitomo Pharma Co., Ltd. Antibody-drug conjugates including hemiasterlin derivative
KR20200131840A (ko) * 2018-03-13 2020-11-24 자임워크스 인코포레이티드 항-her2 2파라토프 항체-약물 접합체 및 이의 사용 방법
JP7465819B2 (ja) 2018-05-29 2024-04-11 イントゥーセル，インコーポレーティッド 新規ベンゾジアゼピン誘導体及びそれらの使用
MX2021004918A (es) 2018-10-31 2021-06-18 Intocell Inc Derivados de benzodiazepina heterociclica fusionada y usos de estos.
HUE059919T2 (hu) 2018-11-09 2023-01-28 Byondis Bv Duokarmicintartalmú antitest-hatóanyag konjugátum szûrhetõ készítményei és ezekkel kapcsolatos eljárások
BR112021011050A2 (pt) 2018-12-11 2021-08-31 Sanofi Ligante peptídico
JP7479302B2 (ja) 2019-02-13 2024-05-08 住友ファーマ株式会社 ヘミアスタリン誘導体とその抗体薬物複合体
CA3127312A1 (en) * 2019-02-13 2020-08-20 Sumitomo Dainippon Pharma Co., Ltd. Hemiasterlin derivative having cysteine residue
CN113024405A (zh) * 2019-12-25 2021-06-25 上海奥博生物医药技术有限公司 一种新的拉考沙胺杂质及其制备方法和用途
CA3170633A1 (en) * 2020-03-09 2021-09-16 David Goeddel Efficient preparation of dolastatin and auristatin analogs through a common intermediate
CA3265385A1 (en) 2022-08-22 2024-02-29 Abdera Therapeutics Inc. DLL3 BINDING MOLECULES AND THEIR USES

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2036891B (en) 1978-12-05 1983-05-05 Windsor Smith C Change speed gear
ES521370A0 (es) 1982-04-12 1985-04-16 Hybritech Inc Un procedimiento para obtener un polidoma.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
CA1282069C (en) 1985-09-12 1991-03-26 Damon L. Meyer Antibody complexes of hapten-modified diagnostic or therapeutic agents
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
FI102355B (fi) 1988-02-11 1998-11-30 Squibb Bristol Myers Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjug aattien valmistamiseksi
US5006652A (en) 1988-08-08 1991-04-09 Eli Lilly And Company Intermediates for antibody-vinca drug conjugates
US5028697A (en) 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5094849A (en) 1988-08-08 1992-03-10 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized vinca analogs via simple organic linkers
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5137877B1 (en) 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
GB9017024D0 (en) 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
US6569834B1 (en) 1992-12-03 2003-05-27 George R. Pettit Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
RU2132334C1 (ru) 1992-12-16 1999-06-27 Басф Акциенгезельшафт Аналог долостатина
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5556623A (en) 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
KR100332254B1 (ko) 1993-10-01 2002-09-27 데이꼬꾸 조끼 세이야꾸 가부시키가이샤 신규인펩티드유도체
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
JP3871713B2 (ja) 1995-05-10 2007-01-24 協和醗酵工業株式会社 新規毒素複合体
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
CA2225325A1 (en) 1997-12-19 1999-06-19 The University Of British Columbia Hemiasterlin analogs
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
JP3715202B2 (ja) 1999-01-28 2005-11-09 中外製薬株式会社 置換フェネチルアミン誘導体
US6468522B1 (en) 1999-07-22 2002-10-22 University Of Medicine And Dentistry Of New Jersey Controlled release of thioamide moiety-containing therapeutic agents
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US6756037B2 (en) 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
WO2002000263A2 (en) 2000-06-14 2002-01-03 Medarex, Inc. Tripeptide prodrug compounds
TWI245034B (en) 2000-07-24 2005-12-11 Matsushita Electric Industrial Co Ltd Capacitor
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6737409B2 (en) 2001-07-19 2004-05-18 Hoffmann-La Roche Inc. Dolastatin 10 derivatives
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
WO2003072754A2 (en) 2002-02-27 2003-09-04 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
RU2342399C2 (ru) 2002-03-22 2008-12-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производные гемиастерлина и их применение при лечении рака
US7064211B2 (en) 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
WO2003090678A2 (en) 2002-04-23 2003-11-06 Ohio State University Antileishmanial dinitroaniline sulfonamides with activity against parasite tubulin
US20050276812A1 (en) * 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
ITMI20021391A1 (it) * 2002-06-25 2003-12-29 Nicox Sa Nitroderivati di inibitori della cicloossigenasi-2
PT2357006E (pt) 2002-07-31 2016-01-22 Seattle Genetics Inc Conjugados de fármacos e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infeciosa
EP1575514A2 (en) * 2002-07-31 2005-09-21 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
CA2495795C (en) 2002-08-16 2011-12-13 Immunogen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
WO2004026293A2 (en) 2002-09-20 2004-04-01 Wyeth Holdings Corporation Hemiasterlin derivatives for treating resistant tumors
AU2003299042A1 (en) 2002-09-20 2004-04-08 Wyeth Holdings Corporation Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
AU2003295808A1 (en) 2002-11-21 2004-06-18 Wyeth Hemiasterlin affinity probes and their uses
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
US7390910B2 (en) 2003-08-08 2008-06-24 Wyeth Compounds for treating tumors
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
AU2004272132A1 (en) 2003-09-15 2005-03-24 The University Of British Columbia Ceratamines A and B, and analogues, syntheses and pharmaceutical compositions thereof
ATE459364T1 (de) 2003-10-22 2010-03-15 Univ Johns Hopkins Verbesserte bakteriolyse-kombinationstherapie für die behandlung von tumoren
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
US7078562B2 (en) 2004-01-19 2006-07-18 Mitsubishi Gas Chemical Company, Inc. Adamantane derivatives and resin compositions using the same as raw material
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
JP5064037B2 (ja) 2004-02-23 2012-10-31 ジェネンテック， インコーポレイテッド 複素環式自壊的リンカーおよび結合体
WO2005112919A2 (en) 2004-05-19 2005-12-01 Medarex, Inc. Self-immolative linkers and drug conjugates
CN101039701A (zh) 2004-08-26 2007-09-19 尼古拉斯皮拉马尔印度有限公司 含有生物可裂解二硫化物连接物的前药和共药
AU2005281359A1 (en) 2004-08-26 2006-03-16 Apparao Satyam Prodrugs and codrugs containing novel bio-cleavable disulfide linkers
US20090130136A1 (en) 2004-09-30 2009-05-21 Miller Louis H Chondroitin Sulphate a Binding Domains
EP1817336B1 (en) 2004-11-12 2019-01-09 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
JP2008521828A (ja) * 2004-11-29 2008-06-26 シアトル ジェネティックス， インコーポレイテッド 操作された抗体およびイムノコンジュゲート
BRPI0519023A2 (pt) 2004-12-13 2008-12-23 Hoffmann La Roche composiÇço farmacÊutica contendo pelo menos um derivado de dolastatina 10
EP1831198B1 (en) 2004-12-22 2009-04-08 AstraZeneca AB Pyridine carboxamide derivatives for use as anticancer agents
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
ES2708763T3 (es) 2005-07-07 2019-04-11 Seattle Genetics Inc Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
LT1912671T (lt) 2005-07-18 2017-12-11 Seattle Genetics, Inc. Vaisto konjugatai, turintys gliukoronido linkerį
AU2006277117B2 (en) 2005-08-05 2013-01-10 Syntarga B.V. Triazole-containing releasable linkers and conjugates comprising the same
NZ566982A (en) 2005-09-26 2011-06-30 Medarex Inc Duocarmycin drug conjugates
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
WO2007103288A2 (en) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
AR065404A1 (es) 2007-02-21 2009-06-03 Medarex Inc Conjugados farmaco-ligando, los que se unen a citotoxinas potentes, composicion farmaceutica que los contienen y su uso para retardar o detener el crecimiento de un tumor en un mamifero
US8476451B2 (en) 2007-07-20 2013-07-02 The Regents Of The University Of California Tubulysin D analogues
JP5095824B2 (ja) 2007-10-10 2012-12-12 ノバルティス アーゲー スピロピロリジン類およびｈｃｖおよびｈｉｖ感染に対するその使用
US20090155289A1 (en) 2007-11-01 2009-06-18 Steve Roberts Furin-cleavable peptide linkers for drug-ligand conjugates
SG172737A1 (en) 2008-01-30 2011-07-28 Pieris Ag Muteins of tear lipocalin having affinity to human c-met receptor tyrosine kinaseand methods for obtaining the same
EP2265283B1 (en) 2008-03-18 2014-09-03 Seattle Genetics, Inc. Auristatin drug linker conjugates
BRPI0911442A2 (pt) 2008-04-30 2019-03-12 Immunogen, Inc. conjugados potentes e ligantes hidrofílicos
KR101764927B1 (ko) 2008-04-30 2017-08-03 이뮤노젠 아이엔씨 가교제 및 그 용도
EP2556747B1 (en) 2008-06-27 2020-12-02 Merus N.V. Antibody producing transgenic mice
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
EP2326349B1 (en) 2008-07-21 2015-02-25 Polytherics Limited Novel reagents and method for conjugating biological molecules
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
EP2865387B1 (en) 2008-11-21 2019-06-12 Københavns Universitet (University Of Copenhagen) Priming of an immune response
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8524214B2 (en) 2009-05-28 2013-09-03 Mersana Therapeutics, Inc. Polyal drug conjugates comprising variable rate-releasing linkers
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
KR20200008045A (ko) 2009-08-28 2020-01-22 아레나 파마슈티칼스, 인크. 칸나비노이드 수용체 조절제
WO2011037192A1 (ja) 2009-09-25 2011-03-31 アステラス製薬株式会社 置換アミド化合物
BR112012024489A2 (pt) 2010-03-29 2016-05-31 Zymeworks Inc anticorpos com função efetora suprimida ou aumentada
PL2560993T3 (pl) 2010-04-20 2024-11-04 Genmab A/S Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
US8722629B2 (en) 2010-06-10 2014-05-13 Seattle Genetics, Inc. Auristatin derivatives and use thereof
WO2012032080A1 (en) 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Stabilised human fc
PH12012500542A1 (en) 2010-09-24 2012-11-12 Astellas Pharma Inc Substituted amide compound
WO2012059882A2 (en) 2010-11-05 2012-05-10 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
EP2678037B1 (en) 2011-02-25 2014-12-03 Lonza Ltd Branched linker for protein drug conjugates
ES2676878T3 (es) 2011-03-03 2018-07-25 Zymeworks Inc. Diseño de armazón de heteromultímero multivalente y constructos
WO2012123957A1 (en) 2011-03-16 2012-09-20 Council Of Scientific & Industrial Research Oligopeptides and process for preparation thereof
WO2012123423A1 (de) 2011-03-16 2012-09-20 Bayer Pharma Aktiengesellschaft N-carboxyalkyl-auristatine und ihre verwendung
AU2012236511B2 (en) 2011-03-30 2016-04-28 Arizona Board Of Regents, For And On Behalf Of, Arizona State University Auristatin tyramine phosphate salts and auristatin aminoquinoline derivatives and prodrugs thereof
RU2610336C2 (ru) 2011-04-21 2017-02-09 Сиэтл Дженетикс, Инк. Новые конъюгаты связывающее соединение - активное соединение (adc) и их применение
ES2690993T3 (es) 2011-05-27 2018-11-23 Ambrx, Inc. Composiciones que contienen y métodos que implican derivados de dolastatina enlazados con aminoácidos no naturales y usos de los mismos
MX345538B (es) 2011-05-27 2017-02-03 Ambrx Inc Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
RU2617402C2 (ru) 2011-06-10 2017-04-25 Мерсана Терапьютикс, Инк. Конъюгаты белок-полимер-лекарственное средство
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
US20130190248A1 (en) 2011-07-26 2013-07-25 Agensys, Inc. Substituted peptide analogs
EP2776409B1 (en) 2011-11-09 2016-02-03 Ensemble Therapeutics Corporation Macrocyclic compounds for inhibition of inhibitors of apoptosis
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
SA112330989B1 (ar) 2011-11-17 2015-07-07 فايزر انك ببتيدات سامة للخلايا ومواد اقتران جسم مضاد وعقار منها
CA2857398A1 (en) 2011-12-05 2013-06-13 Igenica Biotherapeutics, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
US9061000B2 (en) 2012-01-19 2015-06-23 Chao-Han LAI Pharmacological treatment of aortic aneurysm development
ES2676029T3 (es) 2012-02-09 2018-07-16 Var2 Pharmaceuticals Aps Direccionamiento de glicanos de sulfato de condroitina
US9981046B2 (en) 2012-05-15 2018-05-29 Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. Drug-conjugates, conjugation methods, and uses thereof
MX363116B (es) 2012-06-07 2019-03-11 Ambrx Inc Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.
CN104619351B (zh) 2012-06-19 2020-01-21 Ambrx公司 抗cd70抗体药物结合物
EP2872161B1 (en) 2012-06-26 2020-12-16 Del Mar Pharmaceuticals Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations
JP6117921B2 (ja) 2012-07-12 2017-04-19 ハンヂョウ ディーエイシー バイオテック カンパニー リミテッド 細胞毒性剤と細胞結合受容体との共役体
TW201428002A (zh) 2012-11-09 2014-07-16 必治妥美雅史谷比公司 用於抑制細胞凋亡抑制劑之巨環化合物
JP6133431B2 (ja) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
EP2740491A1 (en) 2012-12-05 2014-06-11 Institut Curie Conjugates of the B-subunit of shiga toxin for use as contrasting agents for imaging and therapy
EP2740493A1 (en) 2012-12-05 2014-06-11 Institut Curie Conjugates of the B-subunit of Shiga toxin for anticancer therapies
AU2013364065B2 (en) 2012-12-21 2018-10-04 Altrubio Inc. Hydrophilic self-immolative linkers and conjugates thereof
LT2956173T (lt) 2013-02-14 2017-06-26 Bristol-Myers Squibb Company Tubulizino junginiai, gavimo ir panaudojimo būdai
WO2014126198A1 (ja) 2013-02-15 2014-08-21 株式会社ペルセウスプロテオミクス 抗ｃｄｈ３ヒト化抗体、その薬剤コンジュゲート、及びそれらの使用
MY174813A (en) 2013-03-15 2020-05-16 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
CA2934030A1 (en) 2013-10-15 2015-04-23 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
WO2015095301A2 (en) 2013-12-17 2015-06-25 Irm Llc Cytotoxic peptides and conjugates thereof
CA2935077C (en) 2013-12-27 2022-03-15 Geoffrey C. Winters Sulfonamide-containing linkage systems for drug conjugates
AU2014373640B2 (en) 2013-12-27 2018-08-30 Var2 Pharmaceuticals Aps VAR2CSA-drug conjugates
CA2960899C (en) 2014-09-17 2021-08-17 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
ES2918425T3 (es) 2015-01-28 2022-07-15 Sorrento Therapeutics Inc Conjugados de anticuerpo-fármaco
US10975112B2 (en) 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules

Similar Documents

Publication Publication Date Title
JP2017502047A5 (OSRAM)
CN116196435B (zh) 包含sting激动剂的抗体药物缀合物
JP4095444B2 (ja) ペンタペプチド化合物及びそれに関する使用
ES2996807T3 (en) Biologically active molecules, conjugates thereof, and therapeutic uses
TWI519312B (zh) 脂肪酸菸鹼酸共軛物及其用途
JP2024541059A (ja) Ｂｃｍａモノクローナル抗体及び抗体薬物複合体
JP7257951B2 (ja) 改善された生理化学的特性を有する自己安定性リンカーを用いる薬物コンジュゲート
EP3474901B1 (en) Cleavable tetrazine used in bio-orthogonal drug activation
JP2019073556A (ja) β−グルクロニド−リンカー薬物結合体
JP2019172710A5 (OSRAM)
MX2014007121A (es) Nuevos conjugados de principio activo-ligante (adc) y su uso.
AU2018250312A1 (en) Bioorthogonal compositions
JP2015531750A5 (OSRAM)
JP2020524675A (ja) Ｃｄ３８抗体薬物コンジュゲート
JP2023119064A (ja) 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート
MX345102B (es) Preparacion liofilizada de dipeptidos citotoxicos.
WO2023077129A1 (en) Tetrazine conjugates for in vivo targeted delivery of a payload
CN115052663A (zh) Alk5抑制剂缀合物及其用途
US20240197907A1 (en) Dual-Cleavage Ester Linkers for Antibody-Drug Conjugates
US20250179117A1 (en) Glycoside dual-cleavage linkers for antibody-drug conjugates
TW202423991A (zh) 組織因子抗體-藥物結合物及其用途
JP2015502363A5 (OSRAM)
WO2025059685A1 (en) Methods for in vivo targeted delivery of a payload
CN116783208A (zh) 用于抗体-药物缀合物的糖苷双裂解接头
CN118369123A (zh) 用于有效载荷的体内靶向递送的四嗪缀合物